Explore the Future of China's Biopharmaceutical Industry at Upcoming Seminar

Upcoming Seminar on China's Biopharmaceutical Industry

On November 5, 2025, Seed Planning Co., Ltd., headquartered in Bunkyo, Tokyo, will host a seminar titled "The Current State and Future of China’s Biopharmaceutical Industry: Strategies to Accelerate Drug Development and Commercialization in Japan-China Relations."

Background of the Seminar

In recent years, Chinese pharmaceutical companies have significantly boosted their drug development efforts, leading to a wave of innovative new drugs entering the market. The trend of licensing out drug pipelines to global firms is gaining momentum, with China increasingly becoming a pivotal hub for new drug creation on a global scale. This transformation is expected to continue accelerating in the near future.

The forthcoming seminar aims to bring together prominent figures from China's biopharmaceutical sector to discuss the current landscape of drug discovery in China, the realities of licensing in and out between Chinese and global companies, and the role of AI in drug development and clinical trials.

Seminar Details

- Date and Time: November 5, 2025, from 13:00 to 17:00 (registration starts at 12:15)
- Organizer: Seed Planning Co., Ltd.
- Venue: Seed Planning’s Tokyo Headquarters Seminar Room (8th Floor)

Tokyo, Bunkyo-ku, Yushima 3-19-11, Yushima First Building
Access Information

- Capacity: 40 participants
- Fee: 27,500 yen (including tax and materials)

Participants will receive an invoice for bank transfer payment.

- Target Audience: Healthcare professionals, hospital executives, system administrators, medical-related businesses, government officials, and research institutions.
- Format: On-site seminar

Registration Process

To register, please fill in the form at the following URL:
Registration Form
Please register individually.

- Registration Deadline: November 4, 2025

Seminar Program

Keynote Speech

Topic: Relations between the Chinese Biopharmaceutical Industry, Chinese Society, and Japan
Speaker: Mr. Keiji Kawamoto, Representative of Kawamoto Bio Business Partners

Session 1

Topic: Current State and Trends in China's Biopharmaceutical Industry - Future Cooperation between Japan and China

- Recent licensing agreements with multinational companies, including those from Japan
- Detailed analysis of various indications and modalities, including rare diseases

Speaker: Dr. Cheng Zangjiang, Founder of Tonacea Technology (Beijing) Co., Ltd. (Presentation in Japanese)
Interpreter: Mr. Keiji Kawamoto

Session 2

Topic: Investment Trends of Chinese Biopharmaceutical Companies - Insights on Exit Strategies

- Assessing the stability of companies and the growth potential of China's biotech sector
- Key considerations for Japanese companies collaborating with Chinese biopharmaceutical firms

Speaker: Mr. Zhang Qing, Director of Trinity Innovation Fund (Beijing) (Presentation in English)
Interpreter: Mr. Keiji Kawamoto

Session 3

Topic: The Future of Drug Discovery and Clinical Development Powered by Big Data and AI in China

- Innovations at the forefront of drug discovery and clinical development submissions
- Utilization of Chinese clinical data and AI technologies by Japanese firms

Speaker: Dr. Ni Lin, Founder of LinZight Technology Co., Ltd. (Presentation in Japanese)

Panel Discussion

A Q&A and discussion session regarding challenges and prospects for Japanese companies partnering with Chinese enterprises in license agreements.
Panelists: Dr. Cheng Zangjiang, Mr. Zhang Qing, Dr. Ni Lin
Moderator: Mr. Keiji Kawamoto
Host: Mr. Hideo Ando, Representative of Andy Pharma Partners

Speaker Profiles

- Dr. Cheng Zangjiang: Founder of Tonacea Technology (Beijing) Co., Ltd. and former R&D personnel at multiple Chinese public agencies. Dr. Cheng has played a pivotal role in the development of new drug initiatives and has extensive connections in the industry.
- Mr. Zhang Qing: Director at Trinity Innovation Fund (Beijing), with a vast background in medicinal chemistry and project management within biopharma and investment.
- Dr. Ni Lin: Holds a Ph.D. in Pharmaceutical Sciences from Osaka University; she founded LinZight to provide specialized data analysis and AI solutions for pharmaceutical firms.
- Mr. Keiji Kawamoto: The representative of Kawamoto Bio Business Partners, specializes in international business law and has experience in bridging partnerships between Japanese and Chinese companies.